Merve Korkmaz Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Merve Korkmaz Yilmaz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Esra Hatipoglu
Department of Endocrinology and Metabolism, Basaksehir Cam and Sakura City Hospital University of Health Sciences Istanbul Turkey
5 shared publications - Mutlu Niyazoglu
Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
3 shared publications - Aysel Unver Ozkahraman
Department of Endocrinology and Metabolism, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye
2 shared publications - Eda Kaya
Department of Medicine, University Hospital Knappschaft Kliniken Bochum, Ruhr University Bochum, Bochum, Germany; The Global NASH Council, Washington DC, USA
2 shared publications - Huseyin Karatay
Department of Pathology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
2 shared publications Alican Karakoç
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (10)
Structured physiotherapy improves functional outcomes in acromegalic arthropathy after biochemical remission: a prospective controlled study
Background: Musculoskeletal symptoms frequently persist in acromegaly despite biochemical remission, yet the impact of structured physiotherapy on pain, stiffness, and function remains poorly defined. Objective: This study evaluates the effects of a standardized knee-focused physiotherapy program in controlled acromegaly and identifies clinical predictors of treatment responsiveness. Methods: Thirteen patients with acromegaly in remission and 13 age-, gender-, and BMI-matched individuals with primary knee osteoarthritis completed a 15-session physiotherapy program. Outcomes were assessed pre- and post-intervention using the brief pain inventory (BPI) and WOMAC. Minimal clinically significant difference (MCID) thresholds (≥2 for BPI, ≥10 for WOMAC) determined meaningful improvement. Correlation analyses examined associations between clinical variables and Δ scores. Results: Acromegaly patients showed significant improvements in all BPI and WOMAC domains (P < 0.001). MCID was achieved by 85% for BPI and 100% for WOMAC total. Pain and function improved most, whereas stiffness showed limited responsiveness. Compared with osteoarthritis controls, acromegaly patients demonstrated smaller Δ changes; baseline-adjusted analyses (ANCOVA) indicated that this attenuated response was largely explained by greater baseline severity in the control group, whereas the persistently greater stiffness in acromegaly remained significant even after adjustment. BMI correlated positively with improvements in BPI total (r = 0.63) and BPI pain severity (r = 0.69), while adenoma size correlated negatively with both measures (r = −0.57 and −0.60). BMI showed a negative association with WOMAC total improvement (r = −0.59). Stiffness changes were strongly negatively correlated with pretreatment IGF-1 (r = −0.77). Conclusion: Structured physiotherapy yields clinically meaningful improvements in pain and function in acromegaly, while stiffness appears less reversible and more structurally driven. Early musculoskeletal assessment and physiotherapy integration may enhance long-term management.
- 1 October 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (10)
Open AccessStructured physiotherapy improves functional outcomes in acromegalic arthropathy after biochemical remission: a prospective controlled study
Background: Musculoskeletal symptoms frequently persist in acromegaly despite biochemical remission, yet the impact of structured physiotherapy on pain, stiffness, and function remains poorly defined. Objective: This study evaluates the effects of a standardized knee-focused physiotherapy program in controlled acromegaly and identifies clinical predictors of treatment responsiveness. Methods: Thirteen patients with acromegaly in remission and 13 age-, gender-, and BMI-matched individuals with primary knee osteoarthritis completed a 15-session physiotherapy program. Outcomes were assessed pre- and post-intervention using the brief pain inventory (BPI) and WOMAC. Minimal clinically significant difference (MCID) thresholds (≥2 for BPI, ≥10 for WOMAC) determined meaningful improvement. Correlation analyses examined associations between clinical variables and Δ scores. Results: Acromegaly patients showed significant improvements in all BPI and WOMAC domains (P < 0.001). MCID was achieved by 85% for BPI and 100% for WOMAC total. Pain and function improved most, whereas stiffness showed limited responsiveness. Compared with osteoarthritis controls, acromegaly patients demonstrated smaller Δ changes; baseline-adjusted analyses (ANCOVA) indicated that this attenuated response was largely explained by greater baseline severity in the control group, whereas the persistently greater stiffness in acromegaly remained significant even after adjustment. BMI correlated positively with improvements in BPI total (r = 0.63) and BPI pain severity (r = 0.69), while adenoma size correlated negatively with both measures (r = −0.57 and −0.60). BMI showed a negative association with WOMAC total improvement (r = −0.59). Stiffness changes were strongly negatively correlated with pretreatment IGF-1 (r = −0.77). Conclusion: Structured physiotherapy yields clinically meaningful improvements in pain and function in acromegaly, while stiffness appears less reversible and more structurally driven. Early musculoskeletal assessment and physiotherapy integration may enhance long-term management.
- Open Access
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 712
Clinical and Genetic Characteristics of Pheochromocytoma and Paraganglioma: A Single-Center Experience Including a Rare VHL Variant
Background/Objectives: Advances in the genetic understanding of pheochromocytoma–paraganglioma (PPGL) have considerably refined personalized approaches to diagnosis and management. This study aims to present our institutional experience on the diagnostic characteristics, clinical course, and genetic background of patients with PPGL, in the context of the current literature. Methods: This retrospective analysis included 35 patients diagnosed with PPGL between years 2020 and 2024, all of whom underwent surgical resection and next-generation sequencing for germline mutations in major PPGL susceptibility genes. Clinical presentation, biochemical profile, pathological findings, and follow-up outcomes were compared between mutation-positive and mutation-negative cases. Results: Of the 35 patients with PPGL, germline mutations were identified in 6 patients (17%): 2 in Cluster 1A genes (SDHA, SDHB), 2 in Cluster 1B (VHL), and 2 in Cluster 2 (NF1). Consistent with existing literature, pathogenic germline variants—particularly SDHB and VHL—were identified in our cohort exclusively in patients younger than 30 years (ages 17, 20, and 25). Mutation-positive patients more frequently exhibited noradrenergic or non-secretory profiles (p = 0.01). Among the three non-secretory tumors in the cohort, two harbored genetic mutations (SDHA, NF1). Interestingly, both NF1-positive patients were normotensive—one (c.3496G > A) with a non-secretory tumor and the other (c.2329T > A) presenting at an unusually late age (63 years)—a strikingly atypical spectrum that underscores the phenotypic variability of NF1-associated PPGL. Bilateral disease was observed exclusively in VHL carriers (p = 0.03). Importantly, we identified a rare VHL c.369delG frameshift variant, not previously reported in association with PPGLs, in a patient with PPGL. No significant difference was observed between SDHB loss (p = 0.1) and proliferative indices (mitotic count, Ki-67) (p = 0.07, p = 0.6) between the two groups. During a median follow-up of 24 months (IQR: 18–36), one SDHB-positive patient had a recurrence, while no distant metastases were detected in the remaining mutation carriers. Conclusions: These findings support characteristic clinical patterns among mutation-positive PPGL and underscore the importance of systematic germline testing in all cases—irrespective of age, family history, or biochemical profile—to guide individualized management and enable cascade screening. The identification of a rare VHL c.369delG variant, previously unreported in association with PPGL, within a characteristic VHL-related clinical phenotype highlights the importance of this association. Similarly, atypical NF1 cases emphasize phenotypic variability and reinforce the importance of germline testing even in clinically silent presentations.
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 712
Open AccessClinical and Genetic Characteristics of Pheochromocytoma and Paraganglioma: A Single-Center Experience Including a Rare VHL Variant
Background/Objectives: Advances in the genetic understanding of pheochromocytoma–paraganglioma (PPGL) have considerably refined personalized approaches to diagnosis and management. This study aims to present our institutional experience on the diagnostic characteristics, clinical course, and genetic background of patients with PPGL, in the context of the current literature. Methods: This retrospective analysis included 35 patients diagnosed with PPGL between years 2020 and 2024, all of whom underwent surgical resection and next-generation sequencing for germline mutations in major PPGL susceptibility genes. Clinical presentation, biochemical profile, pathological findings, and follow-up outcomes were compared between mutation-positive and mutation-negative cases. Results: Of the 35 patients with PPGL, germline mutations were identified in 6 patients (17%): 2 in Cluster 1A genes (SDHA, SDHB), 2 in Cluster 1B (VHL), and 2 in Cluster 2 (NF1). Consistent with existing literature, pathogenic germline variants—particularly SDHB and VHL—were identified in our cohort exclusively in patients younger than 30 years (ages 17, 20, and 25). Mutation-positive patients more frequently exhibited noradrenergic or non-secretory profiles (p = 0.01). Among the three non-secretory tumors in the cohort, two harbored genetic mutations (SDHA, NF1). Interestingly, both NF1-positive patients were normotensive—one (c.3496G > A) with a non-secretory tumor and the other (c.2329T > A) presenting at an unusually late age (63 years)—a strikingly atypical spectrum that underscores the phenotypic variability of NF1-associated PPGL. Bilateral disease was observed exclusively in VHL carriers (p = 0.03). Importantly, we identified a rare VHL c.369delG frameshift variant, not previously reported in association with PPGLs, in a patient with PPGL. No significant difference was observed between SDHB loss (p = 0.1) and proliferative indices (mitotic count, Ki-67) (p = 0.07, p = 0.6) between the two groups. During a median follow-up of 24 months (IQR: 18–36), one SDHB-positive patient had a recurrence, while no distant metastases were detected in the remaining mutation carriers. Conclusions: These findings support characteristic clinical patterns among mutation-positive PPGL and underscore the importance of systematic germline testing in all cases—irrespective of age, family history, or biochemical profile—to guide individualized management and enable cascade screening. The identification of a rare VHL c.369delG variant, previously unreported in association with PPGL, within a characteristic VHL-related clinical phenotype highlights the importance of this association. Similarly, atypical NF1 cases emphasize phenotypic variability and reinforce the importance of germline testing even in clinically silent presentations.
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (4) , 583-589
Association of Sleep Quality, Depression, and Quality of Life with Glycemic Control in Patients with Type 2 Diabetes Mellitus
Ejmi Eurasian Journal of Medical Investigation
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (4) , 583-589
Association of Sleep Quality, Depression, and Quality of Life with Glycemic Control in Patients with Type 2 Diabetes Mellitus
Ejmi Eurasian Journal of Medical Investigation
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , 1081-1090
Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature
Amyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tumour burden and markedly elevated prolactin levels, highlighting novel multimodal therapeutic strategies. A 49-year-old man presented with headache and visual disturbance. Imaging revealed a giant pituitary macroadenoma (63 × 84 × 46 mm) with Knosp grade 4 cavernous sinus invasion and clivus erosion. Laboratory investigations revealed marked hyperprolactinemia (prolactin (PRL): 30,969 ng/mL) and autonomous growth hormone (GH) hypersecretion. Histopathology confirmed a sparsely granulated lactotroph tumour with extensive amyloid spherules and dystrophic calcifications (Ki-67: 8%). Notably, immunohistochemistry demonstrated PRL positivity without GH immunoreactivity, suggesting tumour heterogeneity with sampling limitations. Comprehensive systemic amyloidosis screening, the first systematic evaluation reported for this entity, excluded systemic disease. Following surgical debulking with extensive residual disease, postoperative cabergoline treatment resulted in a reduction in the PRL (4,700→927 ng/mL). Given the presence of amyloid-associated dopamine resistance, cabergoline was discontinued, and radiotherapy (RT) (45 Gy) was initiated to control the amyloid burden, followed by temozolomide. Based on evidence from other malignancies suggesting RT-mediated amyloid reduction, cabergoline was reintroduced postradiotherapy without paradoxical tumour growth. Concurrent cabergoline-temozolomide therapy, a novel approach that differs from conventional sequential protocols, achieved a dramatic response: 93.4% prolactin reduction (10,320→677 ng/mL) and 52.4% tumour volume reduction. This superior outcome far exceeded that of initial postsurgical cabergoline monotherapy (80% reduction), suggesting that RT successfully modulated the amyloid burden and restored dopamine sensitivity. This case suggests that RT may restore dopamine agonist sensitivity in patients with amyloid-containing prolactinomas, potentially enabling concurrent dopamine agonist-temozolomide therapy in refractory cases, warranting further validation.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , 1081-1090
Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature
Amyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tumour burden and markedly elevated prolactin levels, highlighting novel multimodal therapeutic strategies. A 49-year-old man presented with headache and visual disturbance. Imaging revealed a giant pituitary macroadenoma (63 × 84 × 46 mm) with Knosp grade 4 cavernous sinus invasion and clivus erosion. Laboratory investigations revealed marked hyperprolactinemia (prolactin (PRL): 30,969 ng/mL) and autonomous growth hormone (GH) hypersecretion. Histopathology confirmed a sparsely granulated lactotroph tumour with extensive amyloid spherules and dystrophic calcifications (Ki-67: 8%). Notably, immunohistochemistry demonstrated PRL positivity without GH immunoreactivity, suggesting tumour heterogeneity with sampling limitations. Comprehensive systemic amyloidosis screening, the first systematic evaluation reported for this entity, excluded systemic disease. Following surgical debulking with extensive residual disease, postoperative cabergoline treatment resulted in a reduction in the PRL (4,700→927 ng/mL). Given the presence of amyloid-associated dopamine resistance, cabergoline was discontinued, and radiotherapy (RT) (45 Gy) was initiated to control the amyloid burden, followed by temozolomide. Based on evidence from other malignancies suggesting RT-mediated amyloid reduction, cabergoline was reintroduced postradiotherapy without paradoxical tumour growth. Concurrent cabergoline-temozolomide therapy, a novel approach that differs from conventional sequential protocols, achieved a dramatic response: 93.4% prolactin reduction (10,320→677 ng/mL) and 52.4% tumour volume reduction. This superior outcome far exceeded that of initial postsurgical cabergoline monotherapy (80% reduction), suggesting that RT successfully modulated the amyloid burden and restored dopamine sensitivity. This case suggests that RT may restore dopamine agonist sensitivity in patients with amyloid-containing prolactinomas, potentially enabling concurrent dopamine agonist-temozolomide therapy in refractory cases, warranting further validation.
- 1 January 2025
- Published by ACTA Endocrinologica Foundation in Acta Endocrinologica (Bucharest)
- Vol. 21 (1) , 131-140
From ‘Null Cell Adenoma’ to Refined Diagnosis: Pitfalls in Pituitary Mass Evaluation
Null cell adenoma (NCA) of the pituitary gland, once considered a distinct subtype of non-functioning pituitary tumors, has been substantially redefined with the advent of transcription factor (TF) immunostaining. The updated WHO classifications emphasize cell lineage differentiation, significantly narrowing the true spectrum of NCAs. To underscore the diagnostic challenges and potential misclassification of NCAs by presenting two illustrative cases and reviewing the evolving diagnostic approach. We describe two diagnostically complex cases initially classified as NCAs due to negative anterior pituitary hormone and TF immunostaining. Both demonstrated atypical clinical features, such as rapid progression and elevated Ki-67 indices, prompting further pathological reassessment. In the first case, follow-up surgeries and additional immunohistochemistry revealed a posterior pituitary tumor—spindle cell oncocytoma. In the second, reevaluation identified hepatocellular carcinoma (HCC) metastasis to the pituitary. These findings highlight the necessity of considering posterior pituitary tumors and metastases in the differential diagnosis of NCAs, especially when clinical or imaging findings suggest alternative etiologies. NCAs must be regarded as a diagnosis of exclusion. Accurate classification depends on thorough clinicopathological correlation, multidisciplinary collaboration, and the use of expanded immunohistochemical panels. Recognition of rare mimickers is crucial for guiding appropriate treatment and improving outcomes.
- 1 January 2025
- Published by ACTA Endocrinologica Foundation in Acta Endocrinologica (Bucharest)
- Vol. 21 (1) , 131-140
From ‘Null Cell Adenoma’ to Refined Diagnosis: Pitfalls in Pituitary Mass Evaluation
Null cell adenoma (NCA) of the pituitary gland, once considered a distinct subtype of non-functioning pituitary tumors, has been substantially redefined with the advent of transcription factor (TF) immunostaining. The updated WHO classifications emphasize cell lineage differentiation, significantly narrowing the true spectrum of NCAs. To underscore the diagnostic challenges and potential misclassification of NCAs by presenting two illustrative cases and reviewing the evolving diagnostic approach. We describe two diagnostically complex cases initially classified as NCAs due to negative anterior pituitary hormone and TF immunostaining. Both demonstrated atypical clinical features, such as rapid progression and elevated Ki-67 indices, prompting further pathological reassessment. In the first case, follow-up surgeries and additional immunohistochemistry revealed a posterior pituitary tumor—spindle cell oncocytoma. In the second, reevaluation identified hepatocellular carcinoma (HCC) metastasis to the pituitary. These findings highlight the necessity of considering posterior pituitary tumors and metastases in the differential diagnosis of NCAs, especially when clinical or imaging findings suggest alternative etiologies. NCAs must be regarded as a diagnosis of exclusion. Accurate classification depends on thorough clinicopathological correlation, multidisciplinary collaboration, and the use of expanded immunohistochemical panels. Recognition of rare mimickers is crucial for guiding appropriate treatment and improving outcomes.
- 3 January 2019
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 28 (3) , 236-238
A Case of Nephrotic Syndrome Presenting With Pulmonary Embolus in a Kidney Transplant Patient
Recurrence of glomerulonephritis (GN) is considered an important cause of allograft failure in kidney transplant recipients. It can present after transplantation with complications that are difficult to manage. In this case report, a 53-year-old woman was admitted to the hospital with abdominal pain and swelling in the right lower quadrant during the first month after kidney transplant. Following hospitalization, she complained of sudden-onset dyspnea and chest pain. Thorax computed tomography examination revealed pulmonary embolism (PE); thus, anticoagulation therapy was started. Her 24-h urine proteinuria was quantified as 16695 mg/day, and due to low albumin levels, she was diagnosed with nephrotic syndrome. However, kidney biopsy could not be performed due to the bleeding tendency of the patient. Due to a probable diagnosis of recurrent focal segmental glomerulosclerosis, plasmapheresis was performed. A total of eight plasmapheresis resulted in a complete recovery of the patient considering her proteinuria. In conclusion, recurrence of GN and development of PE due to nephrotic syndrome are well known, but difficult-to-manage. Thus, nephrology follow-up after kidney transplant is crucial. Cite this article as: Korkmaz M, Kaya E, Karakoç A, Trabulus S, Pekmezci S, Seyahi N. A Case of Nephrotic Syndrome Presenting With Pulmonary Embolus in a Kidney Transplant Patient. Turk J Nephrol 2019; 28(3): 236-8.
- 3 January 2019
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 28 (3) , 236-238
A Case of Nephrotic Syndrome Presenting With Pulmonary Embolus in a Kidney Transplant Patient
Recurrence of glomerulonephritis (GN) is considered an important cause of allograft failure in kidney transplant recipients. It can present after transplantation with complications that are difficult to manage. In this case report, a 53-year-old woman was admitted to the hospital with abdominal pain and swelling in the right lower quadrant during the first month after kidney transplant. Following hospitalization, she complained of sudden-onset dyspnea and chest pain. Thorax computed tomography examination revealed pulmonary embolism (PE); thus, anticoagulation therapy was started. Her 24-h urine proteinuria was quantified as 16695 mg/day, and due to low albumin levels, she was diagnosed with nephrotic syndrome. However, kidney biopsy could not be performed due to the bleeding tendency of the patient. Due to a probable diagnosis of recurrent focal segmental glomerulosclerosis, plasmapheresis was performed. A total of eight plasmapheresis resulted in a complete recovery of the patient considering her proteinuria. In conclusion, recurrence of GN and development of PE due to nephrotic syndrome are well known, but difficult-to-manage. Thus, nephrology follow-up after kidney transplant is crucial. Cite this article as: Korkmaz M, Kaya E, Karakoç A, Trabulus S, Pekmezci S, Seyahi N. A Case of Nephrotic Syndrome Presenting With Pulmonary Embolus in a Kidney Transplant Patient. Turk J Nephrol 2019; 28(3): 236-8.
- 7 July 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (8) , e13345
Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti‐interleukin‐1 drugs emerge as a therapeutic option for colchicine‐resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.Methods: A total of nine patients with FMF amyloidosis treated with canakinumab were enrolled. Laboratory and clinical data were collected from the patient files, electronic database of the hospital and with interviews.Results: Five of the patients were male and four were female (median age: 33, range: 27‐62 years). All of the patients had rapid or gradual disappearance of FMF attacks. The following changes in the laboratory parameters were observed before and after the treatment: C‐reactive protein: 18.31 ± 13.58 mg/L vs 9.98 ± 11.66 mg/L, creatinine clearance: 45.27 ± 21.5 mL/min vs 50.71 ± 22.48 mL/min, and 24‐hour proteinuria: 2381.8 ± 3910.4 mg vs 710.0 ± 1117.5 mg; there were no statistically significant differences on those parameters. One patient developed a reaction to injection while another showed symptoms of Cytomegalovirus pneumonia.Conclusion: Canakinumab can be considered as a safe and efficient drug in preventing the FMF attacks in kidney transplant recipients.
- 7 July 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (8) , e13345
Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti‐interleukin‐1 drugs emerge as a therapeutic option for colchicine‐resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.Methods: A total of nine patients with FMF amyloidosis treated with canakinumab were enrolled. Laboratory and clinical data were collected from the patient files, electronic database of the hospital and with interviews.Results: Five of the patients were male and four were female (median age: 33, range: 27‐62 years). All of the patients had rapid or gradual disappearance of FMF attacks. The following changes in the laboratory parameters were observed before and after the treatment: C‐reactive protein: 18.31 ± 13.58 mg/L vs 9.98 ± 11.66 mg/L, creatinine clearance: 45.27 ± 21.5 mL/min vs 50.71 ± 22.48 mL/min, and 24‐hour proteinuria: 2381.8 ± 3910.4 mg vs 710.0 ± 1117.5 mg; there were no statistically significant differences on those parameters. One patient developed a reaction to injection while another showed symptoms of Cytomegalovirus pneumonia.Conclusion: Canakinumab can be considered as a safe and efficient drug in preventing the FMF attacks in kidney transplant recipients.